**NORTHERN IRELAND MEDICINES MANAGEMENT**

**June 2016  Volume 7, Issue 6**

**NEWSLETTER**

---

**In This Issue**

- Eye Formulary chapter published
- How to access the Renal Drug Handbook
- Licensed demeclocycline back in stock
- Supply of baby milk on Facebook
- NICE guidance — NI endorsements
- Managed Entry decisions

---

**EYE FORMULARY CHAPTER PUBLISHED**

With the increasing number of eye products on the market, product selection can be confusing. A new chapter has been added to the Northern Ireland (NI) Formulary which focuses on the management of dry eye and glaucoma. It is hoped that the new chapter will provide some clarity for healthcare professionals in Northern Ireland.

In addition to the Formulary choices and accompanying prescribing notes, patient information leaflets (PILs) have been produced and are available via the NI Formulary website.

The PILs and the Formulary chapter were developed in conjunction with local ophthalmology specialists.

**Action**

- Refer to the NI Formulary website for Formulary choices and general advice on managing dry eyes and blepharitis (i.e. non-drug options) [http://niformulary.hscni.net](http://niformulary.hscni.net).

---

**HOW TO ACCESS THE RENAL DRUG HANDBOOK**

If you are looking for information on drug dosing in patients with different levels of kidney function, this information can be found in the Renal Drug Handbook. This is available both on-line and as paper copies.

NHS staff in Northern Ireland can access this resource through Health On the Net Northern Ireland (HONNI) [http://www.honni.qub.ac.uk/](http://www.honni.qub.ac.uk/) (registration at a local medical library is required in the first instance — see HONNI website for nearest branch and opening hours).

---

**LICENSED DEMECLOCYCLINE BACK IN STOCK**

Demeclocycline 150mg tablets have been out of stock since Summer 2014. As such, only unlicensed preparations have been available. The licensed Amdipharm brand is now back in stock with wholesalers in Northern Ireland.
The following medicines were considered in June as part of the Northern Ireland Managed Entry process. For details of the outcomes please refer to the Managed Entry section of the Northern Ireland Formulary website: http://niformulary.hscni.net/ManagedEntry/MEdecisions/Pages/default.aspx

- Abiraterone (Zytiga®)
- Alirocumab (Praluent®)
- Bevacizumab (Avastin®)
- Ceftolozane + tazobactam (Zerbaxa®)
- Eltrombopag (Revolade®)
- Evolocumab (Repatha®)
- Idelalisib (Zydelig®)
- Paclitaxel Albumin (Abraxane®)
- Pertuzumab (Perjera®)
- Regorafenib (Stivarga®)
- Simeprevir (Olysio®)

Every effort has been made to ensure that the information included in this newsletter is correct at the time of publication. This newsletter is not to be used for commercial purposes.